Following cases of hepatobiliary toxicity leading to liver decompensation, Eiger has decided to drop its Phase III LIMT-2 trial of peginterferon lambda in chronic hepatitis delta.
https://www.pharmalive.com/wp-content/uploads/2023/09/liver-viruses.jpeg350625BioSpacehttps://www.pharmalive.com/wp-content/uploads/2020/01/Pharmalive_4c-300x37.pngBioSpace2023-09-13 10:13:182023-09-13 10:13:18Eiger discontinues Phase III hepatitis study due to safety concerns
